Loxifrit TH Tablet contains Lornoxicam 8mg and Thiocolchicoside 4mg, a dual-action formulation indicated for the management of musculoskeletal pain, inflammation, and muscle spasms. It helps in relieving joint pain, stiffness, and associated muscular discomfort for patients with acute or chronic conditions.
Lornoxicam, a non-steroidal anti-inflammatory drug (NSAID), reduces pain and inflammation by inhibiting cyclooxygenase enzymes, while Thiocolchicoside, a muscle relaxant, acts on spinal and supraspinal sites to relieve muscle tension and spasms. This combination provides comprehensive symptomatic relief.
For distributors and healthcare suppliers, Loxifrit TH Tablet is a high-demand musculoskeletal therapy product, prescribed by orthopedists, physiotherapists, rheumatologists, and general physicians. Its dual mechanism ensures broad clinical applicability and recurring demand in hospitals, clinics, and specialty centers.
Adding Loxifrit TH Tablet to your pain management and musculoskeletal therapy segment creates strong opportunities in pharmacies, hospitals, orthopedic and physiotherapy clinics, export markets, and third-party manufacturing. Its proven efficacy, dual-action benefit, and strong prescriber acceptance make it a valuable addition to pharmaceutical distribution portfolios.